European Congress of Rheumatology

Patients with inflammatory arthritis experiencing “long COVID” reported significantly worse disease activity.

Higher PROs, which were indicative of worse disease activity, were more likely to be reported in the spring and fall months.

Independent predictors of physical activity avoidance were anxiety symptoms—as determined by HADS—and the SF-36 Physical Component Score.

At the end of the intervention period, all patients displayed a significant reduction in weight of approximately 3 BMI points.

At week 24, 20% of patients were able to achieve gout remission. This percentage increased to 47% at week 52.

Health literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.

The mean percentage change from baseline in lumbar spine bone mineral density was comparable between treatment groups at 18 months.

Jacques-Eric Gottenberg, MD, PhD, discusses the encouraging results of a phase 2 study evaluating nipocalimab for the treatment of Sjögren's syndrome.

A significantly larger proportion of patients in the dotinurad group met the primary endpoint compared with the febuxostat group at week 24.

The primary endpoint was met by 51% of patients in the high dose group and 43% of patients in the low dose group, compared with only 8% of those receiving placebo.

Reductions in the mean number of tender joints from baseline to month 6 were greater among patients in the treatment groups compared with placebo.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

If approved, zasocitinib could become a leading oral treatment for PsA.

Administering canakinumab prophylaxis before a pegloticase infusion prevents new gout glares induced by pegloticase + methotrexate treatment.

A study presented at EULAR 2024 found patients with RA of low socioeconomic status have a high prevalence of fatigue.

Among all groups, fewer men with rheumatic disease were childless compared with controls.

At 8 months follow-up, 86.0% of patients with rheumatoid arthritis were in remission and 94.2% exhibited low disease activity.

CD40L blockade with dazodalibep benefited disease activity scores, including tender and swollen joints, in patients with moderate-to-severe active RA.

Treatment with romosozumab or denosumab demonstrated comparable results among patients with either primary osteoporosis or those with rheumatoid arthritis complicated with osteoporosis over a 24-month period.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

A study presented at EULAR 2024 found tender joint count was linked to depression and illness perception but not anxiety.

Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.

A study presented at EULAR 2024 found a positive correlation between RA disease activity levels and mood disorders.

A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.

EULAR 2024 data link maternal intake of over 252 grams of fish per week with higher risk of juvenile idiopathic arthritis in offspring, but causation is unclear.

A study from EULAR details the ability of the FIRST self-questionnaire to identify fibromyalgia in patients with rheumatoid arthritis.

A post hoc analysis of the MIRROR trial suggests comprehensive gout management should aim for remission, incorporating both uric acid lowering and broader symptom improvements.

Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.